-
Posted by
Two Blokes Tue at 7:15 AM -
Filed in
Stock
-
2 views
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2025 and provided corporate update. Thomas Kuhn, Chief Executive Officer of Poxel, stated: “TWYMEEG\u00ae has further dem.
